Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06108726
Other study ID # xxingxiang
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 18, 2023
Est. completion date October 18, 2025

Study information

Verified date October 2023
Source Northern Jiangsu Province People's Hospital
Contact xu x xiang, Doctor
Phone 87373012
Email liuxy0229@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this single-arm, exploratory clinical study is to evaluate the safety and efficacy of local injection of envafolimab combined with chemotherapy in the first-line treatment of non-small cell lung cancer (NSCLC) patients, and to observe the changes of immune cells in the local immune microenvironment before and after immunotherapy, in order to find new indicators for immunotherapy evaluation.


Description:

In this study, 16 patients with NSCLC were enrolled to explore the clinical effect of chemotherapy combined with local injection of Envafolimab. To determine whether the treatment of metastatic/recurrent NSCLC with Envafolimab is effective, and whether the treatment of Envafolimab combined with chemotherapy can prolong the PFS\OS of patients with NSCLC, and to screen for a more effective treatment mode for Chinese NSCLC patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date October 18, 2025
Est. primary completion date January 18, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. The subjects volunteered to participate in the study, signed the informed consent form, and had good compliance; - 2. ECOG=2 ; - 3.Life expectancy of =12 weeks; - 4.Age =18 years; - 5. Diagnosed by histological examination and/or cytology examination, and imaging evaluation (refer to RECIST 1.1) for advanced central NSCLC; - 6. He had not received systemic chemotherapy previously. - 7.Had at least one measurable tumor lesion according to RECIST v1.1;That is, in CT or MRI detection, the longest diameter of a single lesion is =10mm, or the lymph node is pathologically enlarged, and the short diameter of a single lymph node on CT scan is =15mm; - 8.Have adequate organ function? Exclusion Criteria: - 1.This study was conducted five years prior to the initiation of treatment or concurrently with other malignant tumors. - 2. Have family history of cancer. - 3.had previously undergone any form treatment, such as surgery, chemotherapy, radiation therapy, etc. - 4.Only individuals experiencing grade 1 or higher unmitigated toxic effects (excluding alopecia and fatigue) resulting from previous therapies were eligible for enrollment; neurologic toxicity needed to return to grade 1 or lower or baseline before participation. - 5.Subjects with severe and/or uncontrollable disease progression; - 6.Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome; - 7.Pregnant or lactating women; - 8.Other conditions considered unsuitable for this study by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Envafolimab Injection
Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.

Locations

Country Name City State
China Northern Jiangsu People's Hospital Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Northern Jiangsu Province People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival(OS) OS is defined as the time from randomization to death due to any cause. Up to 2 years
Primary Objective Response Rate(ORR) ORR is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1 Up to 2 years
Primary Progression free survival(PFS) Progression free survival (PFS) is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1). Up to 2 years
Secondary Disease control rate (DCR) DCR is defined as the proportion of subjects with CR, PR, or SD based on RECIST v1.1. Up to 2 years
Secondary Duration of response (DOR) DOR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first. Up to 2 years
Secondary Treatment related adverse events (TRAEs) The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0 from first dose to 30 days post the last dose
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2